Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

Fig. 1

a Absolute counts (×109/L) of different B cell populations; A alemtuzumab cohort, C controls. In the alemtuzumab cohort there was significant reduction in the frequency of CD19+ B cells (p = 0.0041), CD19+CD5+ B cells (p = 0.0175), naïve B cells (CD19+CD27-) (p = 0.0041), and CD19+CD24hiCD38hi B cells (p = 0.003). b Rheumatoid factor (RF) titres (IU) in patients with rheumatoid arthritis (n = 10) pre and post treatment with alemtuzumab. The post treatment titres are either 12 years (n = 8) or 20 years (n = 2) after alemtuzumab administration. We show a clear trend in fall in RF titres in 9/10 patients but this was not statistically significant (p = 0.084). *p <0.05, **p < 0.01

Back to article page